Using Lentiviral Vectors to Target Epstein-Barr Virus Tumors with T-Cell Receptors
Author Information
Author(s): Yang Dongchang, Shao Qing, Sun Hua, Mu Xiaoxin, Gao Yun, Jiang Runqiu, Hou Jiajie, Yao Kun, Chen Yun, Sun Beicheng
Primary Institution: The First Affiliated Hospital of Nanjing Medical University
Hypothesis
Transduction of latent membrane protein 2 (LMP2)-specific T-cell receptors into activated T lymphocytes may provide a universal, MHC-restricted means to treat EBV-associated tumors in adoptive immunotherapy.
Conclusion
LMP2-specific CTLs by lentiviral transduction have the potential use for treatment of EBV-related tumors.
Supporting Evidence
- Vectors containing Vβ 6.7 promoter were found to be optimal for expression in PBMCs.
- Transduced CTLs exhibited significant resistance to tumor cell challenges in mice.
- All groups of transduced CD8+ cells dramatically slowed or abolished the growth of LMP2-positive tumors.
Takeaway
Scientists are trying to help the body fight certain cancers by using special cells that can recognize and attack the cancer. They found a way to make these cells even better using a special tool called a lentiviral vector.
Methodology
The study compared four different T-cell-specific promoters in lentiviral vectors to evaluate TCR gene expression in human primary peripheral blood monocytes and T cell line HSB2.
Limitations
The study only compared T-cell-specific promoters and did not explore other potentially more effective promoters.
Participant Demographics
Healthy human donors provided peripheral blood mononuclear cells (PBMCs).
Statistical Information
P-Value
p<0.05
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website